Modified Arrestin-1 to Enhance Photoreceptor Survival in Retinal Disease

Modified Arrestin-1 delivered to retina with AAV Modified Arrestin-1 binds enolcase-1 without reducing inhibitory effect of enolase-1, an advantage over native protein Slows retinal degeneration, slows loss of photoreceptor ERG function, improves photoreceptor survival Murine model of retinitis pigmentosa

Re-Establishing Immune Tolerance Using for Multiple Sclerosis

Re-establishes immune tolerance, reducing need for long-term therapies and increasing patient comfort and ease of treatment Enables the patient’s own immune system to generate the unique immune regulatory T-Cells specifically needed, permitting a universally applicable treatment AAV gene therapy to have the body make the specific regulatory T-cells needed to regulate immune tolerance MS Mouse […]

Micro-Utrophin/Dystrophin Chimeric Constructs

DMD AAV gene therapy Different mutations and deletions in dystrophin can cause a patient to have an immune response against expressed micro-dystrophin These dystrophin chimeras are designed to avoid neoantigen presentation for a wide range of known dystrophin mutations, reducing potential immune response

AAV Capsid Variants for Gene Therapy

Novel AAV variants that alter the tropisms and improve the transduction efficiency Targeting of skeletal and cardiac muscle over liver Transfection efficiency improved; lower dose required NHP study beginning soon

Countering Obesity in Companion Animals and People with Gene Therapy

Combines administration of GDF15 and a myostatin inhibitor, treating obesity while preventing loss of muscle mass Mice lose adipose tissue while maintaining lean mass, making it a potential therapy for companion animals and humans Different vectors can serve as delivery vehicles, including adeno-associated viral (AAV) vectors